Title:
ピラゾリルベンゾエート配位子を含む金属－有機フレームワーク材料、及びその製造方法
Document Type and Number:
Japanese Patent JP7478761
Kind Code:
B2
Abstract:
Metal-organic framework materials (MOFs) are highly porous entities comprising a multidentate organic ligand coordinated to multiple metal centers, typically as a coordination polymer. Some highly porous MOFs lack stability at ambient conditions. MOFs having ambient condition stability may comprise a plurality of metal clusters (M4O clusters, M=a metal), and a plurality of 4-(1H-pyrazol-4-yl)benzoate ligands coordinated to the plurality of metal clusters to define an at least partially crystalline network structure having a plurality of internal pores. Methods for synthesizing these MOFs may comprise combining a metal source, such as a preformed metal cluster, with 4-(1H-pyrazol-4-yl)benzoic acid, and reacting the preformed metal cluster with the 4-(1H-pyrazol-4-yl)benzoic acid to form a MOF having an at least partially crystalline network structure with a plurality of internal pores defined therein and comprising a plurality of metal clusters coordinated to a multidentate organic ligand comprising 4-(1H-pyrazol-4-yl)benzoate.
Inventors:
Falkovsky, Joseph M
Joshi Yogesh Bui
Abdul Karim, Mary S
Weston, Simon Sea
Joshi Yogesh Bui
Abdul Karim, Mary S
Weston, Simon Sea
Application Number:
JP2021576361A
Publication Date:
May 07, 2024
Filing Date:
May 26, 2020
Export Citation:
Assignee:
ExxonMobil Technology and Engineering Company
International Classes:
B01J20/22; B01J20/28; B01J20/30; C07D231/12; C07F3/06
Domestic Patent References:
| JP2014004519A | ||||
| JP2018538285A | ||||
| JP2004161675A |
Other References:
Christian Heering, Ishtvan Boldog, Vera Vasylyeva, Joaquin Sanchiz and Christoph Janiak,Bifunctional pyrazolate-carboxylate ligands for isoreticular cobalt and zinc MOF-5 analogswith magnetic analysis of the {Co4(μ4-O)} node,CrystEngComm,2013 15,2013年08月16日,9757
Attorney, Agent or Firm:
Norito Yamao
Mitsuru Fukumasa
Mitsuru Fukumasa
Previous Patent: Method and system for projecting images within eye safety limits
Next Patent: Bispecific T cell-engaging antibody constructs
Next Patent: Bispecific T cell-engaging antibody constructs